Izrael - angličtina - Ministry of Health

taro pharmaceutical industries ltd - macrogols; potassium chloride; sodium bicarbonate; sodium chloride - powder for solution - macrogols 315.0 g; potassium chloride 1.1175 g; sodium bicarbonate 4.2840 g; sodium chloride 8.4240 g - mineral salts in combination - mineral salts in combination - bowel cleansing prior to colonoscopy and barium enema x-ray examinations.

Izrael - angličtina - Ministry of Health

taro pharmaceutical industries ltd - oxycodone hydrochloride; paracetamol - tablets - oxycodone hydrochloride 10 mg; paracetamol 325 mg - paracetamol - paracetamol - for the relief of moderate to moderately severe pain.

Izrael - angličtina - Ministry of Health

taro pharmaceutical industries ltd - oxycodone hydrochloride; paracetamol - tablets - paracetamol 325 mg; oxycodone hydrochloride 5 mg - paracetamol, combinations with psycholeptics - paracetamol, combinations with psycholeptics - for the relief of moderate to moderately severe pain.

Izrael - angličtina - Ministry of Health

taro pharmaceutical industries ltd - thioridazine hydrochloride - film coated tablets - thioridazine hydrochloride 10 mg - thioridazine - ridazin is indicated only for schizophrenic patients who fail to show an acceptable response to adequate courses of treatment with other antipsychotic drugs, either because of insufficient effectiveness or the inability to achieve an effective dose due to intolerable adverse effects. thioridazine has not been systematically evaluated in controlled trials in treatment refractory schizophrenic patients and its efficacy in such patients is unknown.

Izrael - angličtina - Ministry of Health

taro pharmaceutical industries ltd - thioridazine hydrochloride - film coated tablets - thioridazine hydrochloride 100 mg - thioridazine - ridazin is indicated only for schizophrenic patients who fail to show an acceptable response to adequate courses of treatment with other antipsychotic drugs, either because of insufficient effectiveness or the inability to achieve an effective dose due to intolerable adverse effects. thioridazine has not been systematically evaluated in controlled trials in treatment refractory schizophrenic patients and its efficacy in such patients is unknown.

Izrael - angličtina - Ministry of Health

taro pharmaceutical industries ltd - thioridazine hydrochloride - film coated tablets - thioridazine hydrochloride 25 mg - thioridazine - ridazin is indicated only for schizophrenic patients who fail to show an acceptable response to adequate courses of treatment with other antipsychotic drugs, either because of insufficient effectiveness or the inability to achieve an effective dose due to intolerable adverse effects. thioridazine has not been systematically evaluated in controlled trials in treatment refractory schizophrenic patients and its efficacy in such patients is unknown.

Izrael - angličtina - Ministry of Health

taro pharmaceutical industries ltd - selenium sulfide - suspension - selenium sulfide 25 mg/ml - selenium sulfide - selenium sulfide - for the treatment of dandruff, seborrheic dermatitis of the scalp and tinea versicolor.

Izrael - angličtina - Ministry of Health

taro pharmaceutical industries ltd - nystatin - suspension - nystatin 100000 iu/ml - nystatin - nystatin - for the treatment of oral fungal infections.

Izrael - angličtina - Ministry of Health

taro pharmaceutical industries ltd - triamcinolone - tablets - triamcinolone 4 mg - triamcinolone - triamcinolone - rheumatology: - active phases of systemic vasculitis: panarteritis nodosa (in patients with concomitant positive hepatitis b serology, the duration of treatment should be restricted to two weeks), polymyalgia rheumatica (pmr), pmr with giant cell arteritis, arteritis temporalis with acute visual loss;- active phases of systemic rheumatic disease: systemic lupus erythematosus, mixed connective tissue disease;- severe progressive forms of active rheumatoid arthritis, e.g. rapidly destructive forms and/or with extra-articular manifestations;- other forms of inflammatory rheumatic arthritis, provided that the severity of symptoms requires it and non-steroidal anti-inflammatory drugs (nsaids) cannot be used:spondylarthritis (ankylosing spondylitis with involvement of peripheral joints, psoriatic arthritis, enteropathic arthropathy with high inflammatory activity);- reactive forms of arthritis;- arthritis in sarcoidosis;- severe systemic form of juvenile idiopathic arthritis (still’s disease) or with iridocyclitis refractory to topical treatment.pulmonary and respiratory tract disorders: - bronchial asthma:for the long-term treatment of severe chronic asthma (category 4) and for treatment of exacerbations in adults and children.- chronic obstructive pulmonary disease (copd):for short-term treatment (max. 14 days) of exacerbations;- upper respiratory tract disorders:for short-term treatment of severe forms of allergic rhinitis in adults after failure of all other treatment alternatives, including topical glucocorticoids.dermatology: - oral initial treatment of extensive, severe, acute skin conditions responsive to glucocorticoids, such as: allergic skin disease (e.g. acute urticaria, contact dermatitis, drug eruption), atopic eczema (acute exacerbations or extensive weeping eczema), pemphigus vulgaris.nephrology: - minimal change glomerulonephritis;- extracapillary proliferative glomerulonephritis (rapidly progressive glomerulonephritis), generally in combination with cytostatics, tapering and ending treatment in goodpasture’s syndrome; for all other forms, long-term continuation of treatment;- idiopathic retroperitoneal fibrosis.

Izrael - angličtina - Ministry of Health

taro pharmaceutical industries ltd - caffeine anhydrous; codeine phosphate; paracetamol - caplets - paracetamol 500 mg; caffeine anhydrous 50 mg; codeine phosphate 15 mg - paracetamol, combinations excl. psycholeptics - paracetamol, combinations excl. psycholeptics - for the relief of pain and coughs and for the reduction of fever accompanied by pain.